The genotoxicity of camptothecin (CPT) and its clinical antineoplastic analogues irinotecan (CPT-11) and topotecan (TPT) were evaluated using the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster. These compounds stabilize and trap the topoisomerase I-DNA complex, preventing the religation step of the breakage/rejoining reaction mediated by the enzyme. The standard version of the wing SMART was used to evaluate the three compounds and to compare the wing spots induced in marker-heterozygous and balancer-heterozygous flies. The results demonstrate that all compounds tested have a significant genotoxic effect in both genotypes analysed. At the same time, a comparison of the clone induction frequencies in marker-heterozygous and balancerheterozygous flies shows that mitotic recombination is the prevalent mechanism through which the three compounds induce all categories of wing spots (78-93% recombination). TPT was the most genotoxic compound, probably because substitutions of amino groups for the 9-carbon of the CPT A ring leads to compounds with greater in vivo activity. CPT and CPT-11 induced, respectively, about 7 and 28 times fewer mutant clones per millimolar exposure unit than TPT.
Introduction
Camptothecins define a new family of anticancer agents, which have eukaryotic DNA topoisomerase (top1) as the sole target. They are able to stabilize and trap top1 in a covalent linkage with DNA (Tanizawa et al., 1995; Desai et al., 1997) , preventing the religation step of the breakage/rejoining reaction mediated by the enzyme. This inhibition is most specific for the rejoining step, resulting in accumulation of a reversible intermediate complex known as the cleavable complex. The net result is that these drugs cause fragmentation of chromosomal DNA, cell death and extensive sister chromatid exchange and chromosomal aberration (Hsiang et al., 1989; Gromova et al., 1993; Liu, 1995) .
Currently, two camptothecin (CPT) derivatives, topotecan (TPT) and irinotecan , are under clinical trials and their ultimate role in cancer therapy appears promising (Slichenmyer et al., 1993; Lynch, 1996) . Studies focused on these two drugs have demonstrated mechanistic differences between them related to the cytotoxic potency and the stability of the cleavable complexes (Tanizawa et al., 1994 (Tanizawa et al., , 1995 Wang et al., 1998) . Consequently, this differential action could influence not only formation of strand breaks during replication but also the likelihood of cell killing or genetic toxicity of these new anticancer agents.
In the present study we employed the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster to assess the structure-activity relationships among this class of compounds with respect to their genotoxic potency. CPT was chosen for this study, together with two analogues, TPT and CPT-11, mainly focusing on their recombinagenic effects in two intervals of chromosome 3 of D.melanogaster.
Materials and methods
Chemicals CPT (CAS no. 7689-03-4) was purchased from Sigma Chemical Co. (St Louis, MO) . was obtained from Yakult Ltd, Japan. TPT (CAS no. 123948-87-8) was tested as the clinical preparation Hycamtin (SmithKline Beecham, NJ), containing 5 mg/ml topotecan HCl. The structural formulae of the three compounds are shown in Figure 1 . All the solutions and dilutions of the compounds were prepared immediately before use. CPT was dissolved in a mixture of 4% ethanol plus 4% Tween 80, while CPT-11 and TPT were diluted in distilled water.
Wing spot test
Two D.melanogaster strains carrying markers on the left arm of chromosome 3 were used: (i) flr 3 /TM3, ri p p sep l(3)89Aa bx 34e e Bd S and (ii) mwh/mwh. For more detailed information on the genetic symbols and descriptions see Lindsley and Zimm (1992) . All stock cultures and experimental populations were maintained at 25 Ϯ 1°C and~60% relative humidity.
Eggs derived from the standard cross (flr 3 /In(3LR) TM3, ri p p sep l(3)89Aa bx 34e e Bd S virgin females crossed with mwh/mwh males) were collected for 8 h on standard medium enriched with baker's yeast. Three days later the larvae were transferred to vials containing 1.5 g Drosophila Instant Medium (Carolina Biological Supply, Burlington, NC) rehydrated with 5 ml of the test solutions. Negative solvent controls were always included. The larvae were allowed to feed on this medium until pupation (~48 h).
Emerged adult flies of the two genotypes, namely marker-heterozygous (mwh ϩ/ϩ flr 3 ) and balancer-heterozygous (mwh ϩ/TM3, Bd s ), were collected and stored in 70% ethanol. Their wings were mounted in Faure's solution and inspected under 400ϫ magnification for the presence of mutant spots. The number of spots as well as their type and size were recorded. On markerheterozygous wings two types of spots could be observed: (i) single spots, either mwh or flr 3 , which can be produced by somatic point mutation, chromosome aberration or mitotic recombination; (ii) twin spots consisting of both mwh and flr 3 subclones, which originated exclusively from mitotic recombination (Graf et al., 1984) . On balancer-heterozygous wings, mwh single spots reflect predominantly somatic point mutation and chromosome aberration, since products of mitotic recombination involving the multiple inverted balancer chromosome (TM3) and its structurally normal homologue are normally non-viable (Szabad et al., 1983) .
Statistical evaluation
To evaluate the genotoxic effects recorded, the frequencies of each type of spot per fly of a treated series were compared with its concurrent negative (solvent) control series. These statistical comparisons were done using the computer program SMART 2.0 (Zordan, unpublished), which employs the χ 2 test for proportions and follows a multiple decision procedure according to Frei and Würgler (1988) . The compounds tested were compared with their respective concurrent control data to obtained the statistical diagnosis. The statistical test used was the χ 2 test for proportions and we tested two hypotheses Tanizawa et al. (1994) . (according to Frei and Würgler, 1988) : (i) the null hypothesis, which assumes that there is no difference in the mutation frequency between control and treated series; (ii) the alternative hypothesis, which postulates a priori that the treatment results in an increased mutation frequency that is m times the spontaneous frequency. The results allow four conclusions: (i) ϩ, positive; (ii) -, negative; (iii) wϩ, weak positive; (iv) i, inconclusive (Frei and Würgler, 1988) .
For the final statistical diagnosis of all positive outcomes, the non-parametric Mann-Whitney U-test with significance levels α ϭ β ϭ 0.05 was used in order to exclude false positive diagnoses (Frei and Würgler, 1995) .
Results

Toxic effects and genetic toxicity
In a pilot dose range finding experiment the chronic toxicity of the three compounds tested was determined quantitatively. For this purpose, batches of 100 larvae were counted and then treated for 48 h with a wide range of concentrations of each compound. After emergence of the adults, the numbers of surviving adult flies were recorded. The resulting survival curves are shown in Figure 2 . All three compounds tested were toxic in 48 h larval feeding experiments. CPT showed the highest toxicity: at 0.1 mM concentration no flies survived. CPT-11 was the drug with the lowest toxicity ( Figure 2 ). Due to the different chronic toxicities of the three compounds, different ranges of exposure concentrations were then chosen for each compound for the genotoxicity experiments. Table I shows a summary of the wing spot test results. In the marker-heterozygous genotype the three compounds showed positive genotoxic effects with clear dose-response effects over the whole range of concentrations used. Statistically significant increases above control levels were observed for all spot categories considered, except for the small single spots at the lowest concentration of CPT. More importantly, these data demonstrate that all top1 blockers significantly increased the frequencies of twin spots, which is evidence of their recombinagenic properties.
The data given in Table I and Figure 3 also show that the top1-targeting drugs were able to induce wing spots in the balancer-heterozygous genotype, although at much lower frequencies than in the marker-heterozygous genotype. In fact, only TPT yielded positive results at all exposure levels for both single (small and large) and total spots. The other two compounds were negative or inconclusive at lower exposure concentrations, especially with respect to the incidence of large single spots. However, the increments in frequencies of total spots are in general statistically higher than those observed for the concurrent negative controls.
Genotoxicity as a function of exposure
For quantitative comparisons between the frequencies of spots induced by the three compounds the data were unified to equimolar standardized values (Table II) . The mwh clone frequencies observed at each exposure level (Table I) were corrected by subtracting the number of spontaneous clones, in such a manner that the corrected frequencies correspond to an estimate of the mutant clones induced by the three top1 poisons. The historical and pooled control frequencies and the numbers of flies analysed in the different treatment series served as a basis for this correction. As shown in Table II , approximated clone induction frequencies per unit of exposure (mM) were calculated through linear extrapolation for each compound (Frei and Würgler, 1996) .
From these data we observe that TPT showed the highest genotoxicity, inducing~2219 mutant clones/10 5 cells/mM. CPT is the second most potent drug (338 mutant clones/10 5 cells/mM), followed by CPT-11 (79 mutant clones/10 5 cells/ mM). This means that CPT and CPT-11 induced, respectively, about 7 and 28 times fewer mutant clones per exposure unit (mM) than TPT (Table II) .
The same correction procedure was also used for the data shown in Figure 4 , except for the fact that the spots were organized into size classes and the standardized frequencies are given as clone induction frequencies per fly. These spot size distributions show that the mean clone size induced by the compounds in the marker-heterozygous flies is larger than expected in the ideal situation (2 i -1 ϭ 2 cells) (Frei et al., 1992) with mean mwh clone sizes of about 15, 6 and 3 cells, respectively, for CPT, TPT and CPT-11 (Table II) . CPT also offered a larger mean clone size in the balancer-heterozygous flies, whereas CPT-11 and TPT induced clones of expected theoretical size (Table II) . The comparatively large clones induced by both CPT and TPT could be related to their more pronounced chemical instability combined with retardation of larval development (Frei and Würgler, 1996) . 
Genotoxicity and recombinagenicity
The proportion of mitotic recombination versus somatic mutation was calculated based on the standardized frequencies (mwh clones/10 5 cells/mM) obtained for the two genotypes as shown in Table II (see also Graf et al., 1992; Graf and Würgler, 1996; Rodriguez-Arnaiz et al., 1996) . The comparison between the two genotypes demonstrates that mitotic recombination is the prevalent mechanism through which the three compounds induce all categories of wing spots. In fact, 78-93% of the spots induced by these drugs are due to recombinational events. CPT has the highest recombinagenic activity (93%). TPT (83%) and CPT-11 (78%) are also quite recombinagenic, but 17-22% of the spots are still of mutational origin.
Discussion
Three points are remarkable with respect to the detailed genetic toxicity analysis of top1-interactive agents and their evaluation 143 in the D.melanogaster SMART. With increased clinical applications, the marked genotoxic effects of top1 inhibitors are becoming more apparent, demonstrating that, like many other anticancer agents, they are a double-edged sword and may themselves induce genetic toxicity (Baguley and Ferguson, 1998) . There is extensive homology between fly DNA top1 and its mammalian counterpart, represented by highly conserved residues that are critical for its structure and function (Hsieh et al., 1992) . Finally, the development of SMART has provided a great asset for simultaneous screening of a wide range of end points available for genetic toxicological studies, including point mutations, deletions, mitotic recombination and, presumably, also chromosomal loss and non-disjunction (Graf et al., 1984; Vogel et al., 1999) . Genotoxicity Our in vivo experiments revealed that all top1-interactive agents tested are genotoxic in the SMART. The major mechanism responsible for the high genetic toxicity observed is the generation of DNA rearrangements, mainly associated with homologous mitotic recombination (Graf et al., 1984; Vogel et al., 1999) . A similar response, represented by high increments in the incidence of this recombinational parameter, has already been demonstrated for CPT in the SMART (Frei and Würgler, 1996; Torres et al., 1998) . These observations become more relevant when one considers that disruption of topoiso- merase function once cleavable complexes are formed may have two general consequences: (i) failure to replicate one of the DNA strands due to interference by the attached topoisomerase may lead to non-homologous recombinational repair; (ii) alternatively, inhibition of topoisomerase function may produce an unfavourable DNA topology leading to homologous or non-homologous recombination (Baguley and Ferguson, 1998) . In fact, there are several lines of evidence suggesting that top1-interactive agents may promote illegitimate (Champoux and Bullock, 1988; Henningfeld and Hecht, 1995) as well as homologous recombination (Cortés et al., 1993a,b; Palitti et al., 1993; Anderson and Berger, 1994) . The genetic changes produced in response to CPT and TPT inactivation of top1 lead to a high level of recombinational (Frei and Würgler, 1988) . c Geometric mean calculated according to Frei et al. (1992) . d Corrections calculated according to Frei et al. (1992) .
events, as illustrated by marked increases in sister chromatid exchanges in cultured mammalian cells (Cortés et al., 1993a,b; Piñero et al., 1996; Ribas et al., 1996) . A high incidence of homologous recombination in Saccharomyces cerevisiae mutants, modified to increase CPT uptake through the cell wall, provides more evidence for the marked recombinagenic activity of these top1 blockers (Nitiss and Wang, 1988) . However, we must keep in mind that the genotoxic effects of top1 blockers are not restricted to recombinational events alone, as these drugs also induced significant enhancements in the frequencies of small and large single spots in balancerheterozygous flies. This indicates that all three CPT derivatives also have mutagenic action, since in this genotype the spots originate exclusively from gene mutation or chromosome aberration (Frei et al., 1992; Frei and Würgler, 1996) . Our data are in agreement with two other reports demonstrating a low level of mutagenic activity of CPT in somatic cells of Drosophila (Frei and Würgler, 1996; Torres et al., 1998) . Accordingly, CPT derivatives tested in cytogenetic bioassays gave high frequencies of chromosomal aberrations, not only as a result of damage induced in S phase but also during G 2 phase (Andersson and Kihlman, 1992; Cortés et al., 1993a,b; Palitti et al., 1993; Piñero et al., 1996) . Studies at the hypoxanthine phosphoribosyltransferase locus also suggest that CPT and TPT induce a mutational process, frequently involving gene deletions (Hashimoto et al., 1995) . Potency The major aim of our study was to investigate the potency of camptothecin compounds as inducers of homologous recombination, trying to establish a relationship with their chemical structure. Our target was somatic cells of the Drosophila wing primordium (wing imaginal disc cells) that undergo approximately five or six rounds of mitotic division, beginning with~780 cells at the start of the treatment and ending up with~30 000 cells when division ceases at the onset of metamorphosis (Frei and Würgler, 1988) . We determined that camptothecins induce mutational and recombinagenic events, using as an end point loss of heterozygosity (LOH) in somatic cells of Drosophila. By means of this experimental procedure, we determined that CPT was the drug with the highest recombinagenic activity (93%), the other two analogues having similar behaviour with respect to this genetic parameter (78-83%). However, in terms of genotoxic potency, TPT was the most potent compound, followed by CPT, with a potency about 7 times lower. Another important observation was the fact that CPT-11 is the least active top1 blocker, inducing somatic genotoxic events at about a 4 times lower rate than its parental compound CPT.
All camptothecins have a basic five ring structure, which is essential for their chemotherapeutic efficacy. The structureactivity relationships of various camptothecin derivatives indicate that the two most distant rings of CPT (rings A and E) are critical for top1 inhibition (Fan et al., 1998; O'Leary and Muggia, 1998) . Substitution of amino groups for the 9-carbon of the CPT A ring leads to compounds with greater in vivo activity, because the cleavable complexes stabilized by these analogues are less reversible (Fan et al., 1998) . TPT [9-(dimethylaminomethyl)-10-hydroxycamptothecin] incorporates a stable basic side chain at position 9 and a hydroxy group at position 10. These replacements greatly increase the antitumour activity of TPT compared with the CPT parent molecule, and could be responsible for its higher genetic toxicity in the SMART. Nevertheless, previous structureactivity studies comparing cytotoxicity and induction of DNA damage, especially chromosomal aberrations, in human colon carcinoma cells and isolated nuclei showed that CPT is the most potent compound, followed by TPT, CPT-11 being inactive in this in vitro analysis (Tanizawa et al., 1994) . Alternatively, CPT-11 retains the lactone ring of CPT but has an additional piperidine side chain at position 10 and an ethyl group at C-7 of the B ring. As already observed, the presence of this bulky substitution at C-10 precludes significant induction of top1-mediated DNA cleavage (Rivory et al., 1996b) . In fact, CPT-11 itself has little, if any, activity in vitro and is thought to exert its anticancer action after biotransformation into SN-38 by carboxylesterases (Kawato et al., 1991; Dodds et al., 1998) . Consequently, the lower genotoxic effect induced by CPT-11 in our system may be due to a low conversion to SN-38 by carboxylesterases, as already demonstrated in human liver (Rivory et al., 1996a; Haaz et al., 1997) .
At least three arguments provide strong evidence that homologous recombination is one of the most important processes required for carcinogenesis: firstly, the demonstration that homologous recombination can be a major mechanism in the LOH required for the second step in the two-step model or for a later event in a multi-step model of carcinogenesis; secondly, the elevated frequencies of homologous recombination and genome rearrangements observed in cells from human patients suffering from cancer-prone diseases. An increased frequency of homologous recombination may increase the likelihood of LOH occurring at an accelerated rate, but also raises the possibility that homologous recombination will cause aberrant genomic rearrangements that may act as the primary step in carcinogenesis. Finally, data from recent reports suggest that homologous recombination can act as an alternative mechanism of telomere maintenance (Bishop and Schiestl, 2001) .
All in all, the high potency of the agents used in this study in inducing homologous recombination rather than mutational events demonstrates that they are a double-edged sword and may themselves contribute to the development of secondary cancer, especially TPT and to a lesser extent CPT-11, which are both in clinical trials.
